Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study

Mayo Clinic1 site in 1 country15,000 target enrollmentApril 23, 2015

ConditionsSolid Tumors Hematologic Malignancies

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Solid Tumors
Sponsor: Mayo Clinic
Enrollment: 15000
Locations: 1
Primary Endpoint: analyze acute and late toxicities using CTCAE 4.03
Status: Active, not recruiting
Last Updated: 11 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To collect and analyze specimens that will correlate with clinical outcomes such as acute and late toxicities, quality of life, local control, and survival of patients treated with photon/proton therapy.

Registry

clinicaltrials.gov

Start Date

April 23, 2015

End Date

April 2026

Last Updated

11 months ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Mayo Clinic

Responsible Party

Principal Investigator

Nadia N. Laack, M.D.

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

•Treated with photon/proton at Mayo Clinic Rochester in Radiation Oncology
•Radiation therapy for curative intent

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

analyze acute and late toxicities using CTCAE 4.03

Time Frame: Patients will be followed for the duration of their life, an expected average of 20 years

analyze quality of life using LASA-3 and FACT-E

Time Frame: Patients will be followed for the duration of their life, an expected average of 20 years

Secondary Outcomes

analyze local control through tumor assessments(Patients will be followed for the duration of their life, an expected average of 20 years)
analyze survival by contacting patient and EMR (electronic medical record) review(Patients will be followed for the duration of their life, an expected average of 20 years)